Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional)
Funding Opportunity RFA-AR-21-015 from the NIH Guide for Grants and Contracts. Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional) (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 31, 2021 Category: Research Source Type: funding

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases and Sjogrens Syndrome (UC2 Clinical
Notice NOT-AR-21-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 25, 2021 Category: Research Source Type: funding

Notice to Extend the Response Date for NOT-AR-19-039 "Request for Information (RFI) on the Lessons Learned from the Accelerating Medicines Partnership Rheumatoid Arthritis and Lupus (AMP RA/SLE Program)"
Notice NOT-AR-20-008 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 28, 2019 Category: Research Source Type: funding

Notice to Extend the Response Date for NOT-AR-19-039 "Request for Information (RFI) on the Lessons Learned from the Accelerating Medicines Partnership Rheumatoid Arthritis and Lupus (AMP RA/SLE Program)"
Notice NOT-AR-20-007 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 3, 2019 Category: Research Source Type: funding

Request for Information (RFI) on the Lessons Learned from the Accelerating Medicines Partnership Rheumatoid Arthritis and Lupus (AMP RA/SLE Program)
Notice NOT-AR-19-039 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 12, 2019 Category: Research Source Type: funding

2014 ASPIRE Rheumatology and Dermatology Research Awards
As competition for research funding increases, the ASPIRE program underscores Pfizer's commitment to supporting research in autoimmune diseases within rheumatology and dermatology. Mission The mission of the 2014 ASPIRE program is to support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases. The ASPIRE Program demonstrates Pfizer’s commitment to supporting promising investigators with an interest in advancing knowledge in defined disease areas within rheumatol...
Source: ScanGrants feed - June 17, 2014 Category: Research Authors: Pfizer Source Type: funding

Notice of Pre-Application Webinar for RFA-AR-14-015 and RFA-AR-14-016 "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus"
Notice NOT-AR-14-019 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 2, 2014 Category: Research Source Type: funding

Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Research Sites (UH2/UH3)
Funding Opportunity Number: RFA-AR-14-016 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.84693.85593.856Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a...
Source: Grants.gov - March 21, 2014 Category: Research Tags: Health Source Type: funding

Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Leadership Center (UM2)
Funding Opportunity Number: RFA-AR-14-015 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.84693.85593.856Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a...
Source: Grants.gov - March 21, 2014 Category: Research Tags: Health Source Type: funding

Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Leadership Center (UM2)
Funding Opportunity RFA-AR-14-015 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis (RA) and Lupus Network Leadership Center. The AMP RA and Lupus Network is designed to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs and peripheral blood cells. (Source: NI...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 21, 2014 Category: Research Source Type: funding

Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Research Sites (UH2/UH3)
Funding Opportunity RFA-AR-14-016 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis (RA) and Lupus Network Research Sites. The AMP RA and Lupus Network is designed to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs and peripheral blood cells. (Source: NIH F...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 21, 2014 Category: Research Source Type: funding

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating Medicines Partnership Rheumatoid Arthritis/Lupus: Leadership Center (UM2)
Notice NOT-AR-14-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 21, 2014 Category: Research Source Type: funding

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating Medicines Partnership Rheumatoid Arthritis/Lupus Research Sites (UH2/UH3)
Notice NOT-AR-14-014 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 21, 2014 Category: Research Source Type: funding

Request for Information (RFI): Input on the Development of a Consortium for Signaling Networks to Critical Targets (CONNECT) in Rheumatoid Arthritis, Lupus and other Autoimmune Conditions
Notice NOT-AR-14-012 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 20, 2013 Category: Research Source Type: funding

Rheumatology Research Foundation Disease Targeted Research Grants
Through our disease targeted research initiative, the Rheumatology Research Foundation is committed to funding innovative research that is not being done elsewhere, which will impact medical breakthroughs in rheumatoid arthritis and other rheumatic diseases. The important work being done through this program is integral in our quest to find a cure. Through this program, the Foundation seeks to support investigator-initiated projects that address basic, translational and clinical aspects of inflammatory arthritis. Outcomes from these projects should lead to new insights into the etiology, pathogenesis and treatment...
Source: ScanGrants feed - August 22, 2013 Category: Research Authors: Rheumatology Research Foundation Source Type: funding